Previous 10 |
home / stock / anpdf / anpdf news
ANTA Sports ( ANPDY ) recently held its annual Investor Day event , where management provided an update on its immediate and mid to long-term financial outlook, strategies for positioning its brands globally as well as the progress the company has made with regards to the acquisition of Amer ...
Lead author: Frank Wang. Source: insideretail.asia Overview ANTA Sports Products Limited ( ANPDY ) ( ANPDF ) is a leading sportswear company in China, principally engaging in the design, research, development, manufacture, marketing, and trade of sporting footwear, apparel, and acc...
Source: jingdaily.com . Overview China has the third-largest consumer market in the world by household final consumption expenditure, after only the US and the EU. The country is evolving incredibly fast and is going through a profound transformation in terms of consumer behavior - e.g....
Source: Yahoo Finance . Overview I believe that many investors look at the earnings to value a stock. I also believe that many of them ignore the fact that every net income generated may come in different quality. It is not only the final absolute number but also (and even more importan...
News, Short Squeeze, Breakout and More Instantly...
ANTA Sports Products Limited Company Name:
ANPDF Stock Symbol:
OTCMKTS Market:
BioHarvest Sciences Inc (CNVCF) is expected to report for quarter end 2023-12-31 QS Energy Inc (QSEP) is expected to report for Q4 2023 NKGen Biotech Inc. (NKGN) is expected to report for Q4 2023 Cal-Maine Foods Inc. (CALM) is expected to report for Q3 2024 Davide Campari (DVDCF) ...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...